MedPath
Found 1 clinical trials|View Analysis
Sort by:

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Elrantamab
Device: clonoSEQ
First Posted Date
2024-07-03
Last Posted Date
2024-12-24
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
65
Registration Number
NCT06483100
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath